Eurofarma has become aware of Anvisa’s (National Health Surveillance Agency) recall action, which has affected the availability in the market of the so-called “sartans” (losartan, valsartan, olmesartan, irbesartan, telmisartan, candesartan), and would like to inform that its products have not been affected and are free of any impurity related to the utilization of those active pharmaceutical inputs.

Attested by an inspection performed by Anvisa in the last month of March, Eurofarma continues to normally fulfill the market demand with its products: Holmes H® (olmesartan medoxomil + hydrochlorothiazide), Zart® (losartan potassium), Zart H® (losartan potassium + hydrochlorothiazide) and Vartaz® (valsartan), in addition to the respective generic drugs containing the active principles losartan, valsartan, olmesartan and irbesartan.

The inspection undertaken by Anvisa evaluated 111 medicines and supervised 29 companies, including industries, importers and distributors, when the presence of impurities in some of those suppliers was verified. In order to provide support to the population at large and the medical class, Anvisa has made available in its website the products, brands and batches related to the suspended medicines and a note with orientations and clarifications about the abovementioned facts, which can be accessed by clicking here.

Eurofarma, for more than 45 years dedicated to offering access to health and quality of life to people, counts on a strict quality standard to produce medicines certified by regulatory authorities for its more than 280 brands and 620 presentations.

We would like to thank you for your trust in our products, and will be available to clarify any doubt you may have at 0800-704-1993 or at